A bicentric, randomised, double-blind placebo-controlled clinical study confirms Memophenol effectiveness on seniors’ memory
Activ’Inside, the France-based botanical ingredient supplier, publishes a new study on Memophenol in the Journal of Gerontology. The clinical study shows an association of specific polyphenols from grape and blueberry that improves episodic memory in healthy elderly people.
This study aimed to evaluate the effect of a 6 months dietary supplementation with a Polyphenols-Rich Extract from Grape and Blueberry (PEGB, trademark Memophenol by Activ’Inside) on memory of healthy elderly subjects. The study involved 215 healthy seniors aged between 60-70 years old, orally supplemented with 300 mg twice a day of Memophenol.
Both learning, short and long-term memories were assessed using validated Neuropsychological tests from the Cambridge Neuropsychological Test Automated Battery (CANTAB). The two tests were used before and after 6 months of supplementation:
The population was split into quartiles according to their corresponding baseline scores. Such approach allows selecting subjects according to their basal cognitive decline level.
Figure 1: PAL score at baseline of the study population. N=190.
To evaluate how Memophenol could correct a more pronounced memory loss, its effectiveness was evaluated on subjects with the worst PAL score at baseline (decliners) (figure 1).
Figure 2: Memophenol TM efficacy on VRM-FR test.
After 6 months of supplementation, in the total population, the study shows that subjects supplemented with Memophenol significantly improves their Verbal Free Recall Recognition Memory scores as shown in Figure 2.
In addition, the subjects having the most important cognitive decline at baseline (t=0), also called “decliners”, significantly reduce the number of errors on the PAL test, therefore highlighting episodic memory improvements. This decrease is associated to 24% less errors versus placebo (figure 3).
Finally, the study shows that these cognitive improvements are interestingly associated with higher urinary concentration specific flavan-3-ols metabolites in the Memophenol group, confirming that Memophenol supplementation improves memory on seniors with a high bioavailability.
Figure 3: Memophenol TM efficacy on PAL test assessed on decliners.
Thanks to this new study, Activ’Inside confirms the effectiveness of Memophenol on the age-related cognitive decline.
“This publication is a new piece of the Memophenol puzzle. Indeed, fruit of a four year international research programme, Memophenol is supported by not less than ten publications and one patent.” says Benoit Lemaire, Chief Executive Officer at Activ’Inside.
Recently, Activ’Inside also published a new 12 year follow up epidemiological study conducted with Inserm and Harvard, showing that polyphenols intake can prevent cognitive decline.
Memophenol is Activ’Inside's innovative active formulation supported by science. Memophenol results from a four year international research programme initiated and led by Activ’Inside. This programme of 4.2 million euros, involved ten academics and industrial partners, as well as 22 scientists, PhD and engineers well recognised for their expertise in the fields of chemistry and biology of polyphenols, neuroscience and engineering of nutritional active ingredients.
The project started with data from epidemiological studies. Polyphenols and specifically flavonoids are have shown preventive effects on cognitive decline. Since that, several in-vitro and in-vivo tests have been performed, as well as a large-scale clinical study. The mechanism of action has been identified as Memophenol improves neurogenesis and synaptic plasticity, thanks to its unique profile in bioavailable polyphenols.
The effectiveness of Memophenol has also been approved by students.